What is M Ventures? M Ventures is the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany, the German science and technology group with operations spanning pharmaceuticals, life science tools and bioprocessing, and electronics materials. Founded in 2009 with an initial focus on healthcare drug development, M Ventures has

Why non-dilutive capital sometimes cuts against the stock Royalty monetisation is sold as the friendliest capital a biotech can raise. Most of the time, the market agrees. The interesting question is the exception: the deals where a non-dilutive, roughly value-neutral transaction takes a fifth of the equity off in a

Two things in pharmaceutical finance carry the name of the same Swiss city, and they are starting to collide. The first Basel is the one this newsletter follows. It is the city on the Rhine where Roche and Novartis turn chemistry into product, where the monoclonal antibody was first made,

Insurance once sat at the center of pharmaceutical royalty finance. The two foundational securitizations of the asset class both relied on a third-party guarantor standing behind the notes: BioPharma Royalty Trust I in 2000 and Royalty Pharma Finance Trust in 2003. In the 2003 deal, the guarantor was the rating.

The week in numbers Disclosed cash and committed capital first. The milestone-inclusive "up to" ceilings are noted second, not led with: where an upfront or a committed amount is disclosed, that is the number to anchor on. * $650M upfront: Pfizer to Innovent on signing of the global oncology

Both are quoted as a percentage of net sales. That shared unit is the entire source of the confusion, and untangling it is the point of this explainer.

METiS TechBio Co., Ltd. is a Hong Kong-listed Chinese tech-bio company applying AI-driven nanomaterial design to drug formulation and delivery, with R&D centres in Beijing, Hangzhou and Cambridge, Massachusetts. Discovery and formulation are conducted on a proprietary platform branded NanoForge, with three application layers (AiTEM for small-molecule formulation,

What is Water Street Healthcare Partners? Water Street Healthcare Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. It was founded in 2005 by Tim Dugan alongside Jim Connelly, the former president and chief operating officer of Caremark International, and Kip Kirkpatrick. All three had previously

The fulcrum security is the most senior class in a debtor's capital structure that does not recover in full under a plan of reorganization. Classes above it are paid in cash, reinstated, or cashed out at par.